Which has higher valuation & earnings, CLLS or IMTX?

Cellectis has higher revenue and earnings than Immatics. Cellectis is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cellectis $79.59M 4.29 -$67.59M -$0.65 N/A Immatics $54.60M 21.93 -$222.26M -$1.86 N/A

Is CLLS or IMTX more profitable?

Cellectis has a net margin of -102.34% compared to Immatics' net margin of -495.71%. Immatics' return on equity of -47.41% beat Cellectis' return on equity. Company Net Margins Return on Equity Return on Assets Cellectis -102.34% -94.19% -21.34% Immatics -495.71% -47.41% -39.45%

Does the media refer more to CLLS or IMTX?

In the previous week, Immatics had 4 more articles in the media than Cellectis. MarketBeat recorded 5 mentions for Immatics and 1 mentions for Cellectis. Cellectis' average media sentiment score of 0.30 beat Immatics' score of -0.35 indicating that Cellectis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectis 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immatics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has better valuation and earnings, CLLS or ALVO?

Alvotech has higher revenue and earnings than Cellectis. Alvotech is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cellectis $79.59M 4.29 -$67.59M -$0.65 N/A Alvotech $588.90M 2.27 $27.92M -$0.61 N/A

Is CLLS or ALVO more profitable?

Alvotech has a net margin of -36.31% compared to Cellectis' net margin of -102.34%. Alvotech's return on equity of -11.92% beat Cellectis' return on equity. Company Net Margins Return on Equity Return on Assets Cellectis -102.34% -94.19% -21.34% Alvotech -36.31% -11.92% -11.73%

Does the media prefer CLLS or ALVO?

In the previous week, Alvotech had 18 more articles in the media than Cellectis. MarketBeat recorded 19 mentions for Alvotech and 1 mentions for Cellectis. Cellectis' average media sentiment score of 0.30 beat Alvotech's score of 0.16 indicating that Cellectis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectis 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alvotech 3 Very Positive mention(s) 3 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has better earnings and valuation, CLLS or SVRA?

Cellectis has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cellectis $79.59M 4.29 -$67.59M -$0.65 N/A Savara N/A N/A -$118.84M -$0.58 N/A

Is CLLS or SVRA more profitable?

Savara has a net margin of 0.00% compared to Cellectis' net margin of -102.34%. Savara's return on equity of -90.28% beat Cellectis' return on equity. Company Net Margins Return on Equity Return on Assets Cellectis -102.34% -94.19% -21.34% Savara N/A -90.28% -68.95%

Does the media prefer CLLS or SVRA?

In the previous week, Cellectis and Cellectis both had 1 articles in the media. Cellectis' average media sentiment score of 0.30 beat Savara's score of -0.60 indicating that Cellectis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectis 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Savara 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Which has higher valuation and earnings, CLLS or KURA?

Cellectis has higher revenue and earnings than Kura Oncology. Cellectis is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cellectis $79.59M 4.29 -$67.59M -$0.65 N/A Kura Oncology $67.48M 15.67 -$278.67M -$3.37 N/A

Is CLLS or KURA more profitable?

Cellectis has a net margin of -102.34% compared to Kura Oncology's net margin of -384.30%. Cellectis' return on equity of -94.19% beat Kura Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Cellectis -102.34% -94.19% -21.34% Kura Oncology -384.30% -207.18% -45.17%

Does the media prefer CLLS or KURA?

In the previous week, Kura Oncology had 16 more articles in the media than Cellectis. MarketBeat recorded 17 mentions for Kura Oncology and 1 mentions for Cellectis. Kura Oncology's average media sentiment score of 0.79 beat Cellectis' score of 0.30 indicating that Kura Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectis 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kura Oncology 8 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CLLS or SANA?

In the previous week, Sana Biotechnology had 5 more articles in the media than Cellectis. MarketBeat recorded 6 mentions for Sana Biotechnology and 1 mentions for Cellectis. Sana Biotechnology's average media sentiment score of 0.56 beat Cellectis' score of 0.30 indicating that Sana Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectis 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sana Biotechnology 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Cellectis (CLLS) Competitors

$3.40 -0.07 (-2.02%)

As of 08/21/2026 03:59 PM Eastern

Compare

CLLS vs. IMTX, ALVO, SVRA, KURA, and SANA

Should you buy Cellectis stock or one of its competitors? Cellectis's main competitors and comparable companies include Immatics (IMTX), Alvotech (ALVO), Savara (SVRA), Kura Oncology (KURA), and Sana Biotechnology (SANA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Cellectis compare to Immatics?

Cellectis (NASDAQ:CLLS) and Immatics (NASDAQ:IMTX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, media sentiment, analyst recommendations and dividends.

Cellectis has a beta of 2.91, suggesting that its stock price is 191% more volatile than the broader market. Comparatively, Immatics has a beta of 1.33, suggesting that its stock price is 33% more volatile than the broader market.

Cellectis currently has a consensus price target of $7.00, suggesting a potential upside of 105.88%. Immatics has a consensus price target of $20.80, suggesting a potential upside of 132.92%. Given Immatics' higher probable upside, analysts clearly believe Immatics is more favorable than Cellectis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Cellectis has higher revenue and earnings than Immatics. Cellectis is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis	$79.59M	4.29	-$67.59M	-$0.65	N/A
Immatics	$54.60M	21.93	-$222.26M	-$1.86	N/A

Cellectis has a net margin of -102.34% compared to Immatics' net margin of -495.71%. Immatics' return on equity of -47.41% beat Cellectis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectis	-102.34%	-94.19%	-21.34%
Immatics	-495.71%	-47.41%	-39.45%

63.9% of Cellectis shares are owned by institutional investors. Comparatively, 64.4% of Immatics shares are owned by institutional investors. 16.4% of Cellectis shares are owned by company insiders. Comparatively, 3.3% of Immatics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Immatics had 4 more articles in the media than Cellectis. MarketBeat recorded 5 mentions for Immatics and 1 mentions for Cellectis. Cellectis' average media sentiment score of 0.30 beat Immatics' score of -0.35 indicating that Cellectis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectis	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immatics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Cellectis beats Immatics on 10 of the 17 factors compared between the two stocks.

How does Cellectis compare to Alvotech?

Cellectis (NASDAQ:CLLS) and Alvotech (NASDAQ:ALVO) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Alvotech has a net margin of -36.31% compared to Cellectis' net margin of -102.34%. Alvotech's return on equity of -11.92% beat Cellectis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectis	-102.34%	-94.19%	-21.34%
Alvotech	-36.31%	-11.92%	-11.73%

63.9% of Cellectis shares are owned by institutional investors. 16.4% of Cellectis shares are owned by company insiders. Comparatively, 0.5% of Alvotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Alvotech has higher revenue and earnings than Cellectis. Alvotech is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis	$79.59M	4.29	-$67.59M	-$0.65	N/A
Alvotech	$588.90M	2.27	$27.92M	-$0.61	N/A

In the previous week, Alvotech had 18 more articles in the media than Cellectis. MarketBeat recorded 19 mentions for Alvotech and 1 mentions for Cellectis. Cellectis' average media sentiment score of 0.30 beat Alvotech's score of 0.16 indicating that Cellectis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectis	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alvotech	3 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Cellectis presently has a consensus target price of $7.00, indicating a potential upside of 105.88%. Alvotech has a consensus target price of $7.60, indicating a potential upside of 71.56%. Given Cellectis' stronger consensus rating and higher possible upside, research analysts plainly believe Cellectis is more favorable than Alvotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Alvotech	2 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.14

Cellectis has a beta of 2.91, indicating that its share price is 191% more volatile than the broader market. Comparatively, Alvotech has a beta of 0.18, indicating that its share price is 82% less volatile than the broader market.

Summary

Cellectis beats Alvotech on 10 of the 17 factors compared between the two stocks.

How does Cellectis compare to Savara?

Cellectis (NASDAQ:CLLS) and Savara (NASDAQ:SVRA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.

Cellectis has a beta of 2.91, suggesting that its stock price is 191% more volatile than the broader market. Comparatively, Savara has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market.

Cellectis has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis	$79.59M	4.29	-$67.59M	-$0.65	N/A
Savara	N/A	N/A	-$118.84M	-$0.58	N/A

Cellectis currently has a consensus target price of $7.00, indicating a potential upside of 105.88%. Savara has a consensus target price of $10.14, indicating a potential upside of 81.45%. Given Cellectis' higher possible upside, equities research analysts plainly believe Cellectis is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Savara has a net margin of 0.00% compared to Cellectis' net margin of -102.34%. Savara's return on equity of -90.28% beat Cellectis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectis	-102.34%	-94.19%	-21.34%
Savara	N/A	-90.28%	-68.95%

In the previous week, Cellectis and Cellectis both had 1 articles in the media. Cellectis' average media sentiment score of 0.30 beat Savara's score of -0.60 indicating that Cellectis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectis	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Savara	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

63.9% of Cellectis shares are held by institutional investors. Comparatively, 87.9% of Savara shares are held by institutional investors. 16.4% of Cellectis shares are held by insiders. Comparatively, 5.3% of Savara shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Cellectis beats Savara on 8 of the 14 factors compared between the two stocks.

How does Cellectis compare to Kura Oncology?

Cellectis (NASDAQ:CLLS) and Kura Oncology (NASDAQ:KURA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

63.9% of Cellectis shares are held by institutional investors. 16.4% of Cellectis shares are held by company insiders. Comparatively, 7.6% of Kura Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Cellectis has a net margin of -102.34% compared to Kura Oncology's net margin of -384.30%. Cellectis' return on equity of -94.19% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectis	-102.34%	-94.19%	-21.34%
Kura Oncology	-384.30%	-207.18%	-45.17%

In the previous week, Kura Oncology had 16 more articles in the media than Cellectis. MarketBeat recorded 17 mentions for Kura Oncology and 1 mentions for Cellectis. Kura Oncology's average media sentiment score of 0.79 beat Cellectis' score of 0.30 indicating that Kura Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectis	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kura Oncology	8 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cellectis has higher revenue and earnings than Kura Oncology. Cellectis is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis	$79.59M	4.29	-$67.59M	-$0.65	N/A
Kura Oncology	$67.48M	15.67	-$278.67M	-$3.37	N/A

Cellectis presently has a consensus price target of $7.00, indicating a potential upside of 105.88%. Kura Oncology has a consensus price target of $25.62, indicating a potential upside of 115.44%. Given Kura Oncology's higher probable upside, analysts clearly believe Kura Oncology is more favorable than Cellectis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Cellectis has a beta of 2.91, suggesting that its stock price is 191% more volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market.

Summary

Cellectis beats Kura Oncology on 11 of the 17 factors compared between the two stocks.

How does Cellectis compare to Sana Biotechnology?

Cellectis (NASDAQ:CLLS) and Sana Biotechnology (NASDAQ:SANA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk.

Cellectis has higher revenue and earnings than Sana Biotechnology. Cellectis is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis	$79.59M	4.29	-$67.59M	-$0.65	N/A
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.76	N/A

Sana Biotechnology has a net margin of 0.00% compared to Cellectis' net margin of -102.34%. Cellectis' return on equity of -94.19% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectis	-102.34%	-94.19%	-21.34%
Sana Biotechnology	N/A	-103.02%	-39.16%

Cellectis has a beta of 2.91, meaning that its share price is 191% more volatile than the broader market. Comparatively, Sana Biotechnology has a beta of 2.16, meaning that its share price is 116% more volatile than the broader market.

63.9% of Cellectis shares are held by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are held by institutional investors. 16.4% of Cellectis shares are held by company insiders. Comparatively, 25.4% of Sana Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Sana Biotechnology had 5 more articles in the media than Cellectis. MarketBeat recorded 6 mentions for Sana Biotechnology and 1 mentions for Cellectis. Sana Biotechnology's average media sentiment score of 0.56 beat Cellectis' score of 0.30 indicating that Sana Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectis	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sana Biotechnology	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Cellectis currently has a consensus target price of $7.00, indicating a potential upside of 105.88%. Sana Biotechnology has a consensus target price of $9.33, indicating a potential upside of 138.70%. Given Sana Biotechnology's higher probable upside, analysts plainly believe Sana Biotechnology is more favorable than Cellectis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Cellectis and Sana Biotechnology tied by winning 8 of the 16 factors compared between the two stocks.

Get Cellectis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLLS vs. The Competition

Export

Metric	Cellectis	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$341.65M	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	-5.23	11.62	272.60	24.24
Price / Sales	4.29	1,338.17	618.96	99.81
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	8.29	16.80	13.05	6.20
Net Income	-$67.59M	-$12.50M	$3.47B	$348.59M
7 Day Performance	11.48%	3.29%	2.09%	0.08%
1 Month Performance	22.74%	8.23%	6.64%	3.88%
1 Year Performance	19.30%	55.05%	25.02%	16.98%

Cellectis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLLS Cellectis	1.951 of 5 stars	$3.40 -2.0%	$7.00 +105.9%	+19.3%	$341.65M	$79.59M	N/A	290	Gap Down
IMTX Immatics	1.7738 of 5 stars	$9.01 -2.6%	$20.80 +131.0%	+56.9%	$1.21B	$37.30M	N/A	260	News Coverage Earnings Report
ALVO Alvotech	2.8261 of 5 stars	$3.95 +1.7%	$7.60 +92.6%	-47.6%	$1.19B	$588.90M	N/A	1,460	Trending News Earnings Report
SVRA Savara	1.8071 of 5 stars	$5.36 -0.3%	$10.14 +89.4%	+76.9%	$1.10B	N/A	N/A	20
KURA Kura Oncology	3.1502 of 5 stars	$12.34 +9.4%	$25.62 +107.7%	+55.4%	$1.10B	$77.23M	N/A	130	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLLS) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cellectis (CLLS) Competitors